Zenith Strengthens its Management Team with Key Appointments
News Sep 09, 2014
Zenith Epigenetics Corp. has announced that it has appointed Joy Zhu, MD, PhD, as Chief Medical Officer, Sanjay Lakhotia, PhD, as Chief Business Officer, and Michael Yakes, PhD, as Vice President Drug Discovery and Exploratory Development.
Dr. Zhu joins Zenith at a pivotal time, just ahead of the first-in-human oncology clinical trials investigating Zenith's proprietary BET inhibitor, ZEN-3365. Dr. Zhu has over 20 years of oncology clinical development experience and has led the design and execution of multiple clinical trials including those resulting in the approval of successful products such as SUTENTÒ and XGEVA.
Prior to joining Zenith, Dr. Zhu held leadership positions at SUGEN/Pfizer, S*BIO Pte Ltd, Amgen, JNJ, and Novartis. Most recently, Dr. Zhu led oncology clinical development at Halozyme Therapeutics.
Dr. Lakhotia brings significant business, operational, and product development expertise to Zenith, with more than two decades of experience at innovative pharmaceutical and biotech companies, including Wyeth Pharmaceuticals, MedImmune, Onyx Pharmaceuticals, Portola Pharmaceuticals, and Pathway Therapeutics. He has contributed to the business development and product development efforts for significant products such as Prevnar, Nexavar, and FluMist.
Dr. Yakes has over 15 years of experience in the discovery and development of novel cancer therapeutics. Prior to joining Zenith, Dr. Yakes held the position of Senior Director, Translational Biology at Cleave Biosciences.
Prior to Cleave Biosciences, he held positions of increasing responsibility at Exelixis, making major contributions to the preclinical characterization and IND/NDA filings for COMETRIQ (cabozantanib).
Dr. Julie Cherrington, President and CEO of Zenith, remarked, "I am very excited to welcome Joy, Sanjay and Mike to Zenith's management team. We have a great foundation to develop a best in class BET inhibitor for the treatment of hematological malignancies and solid tumors in select patient populations. This is a pivotal step in building a leading epigenetics company".
$26.5M Study on Aggressive Prostate Cancer in African-American Men BeginsNews
The largest coordinated research effort to study biological and non-biological factors associated with aggressive prostate cancer in African-American men has begun.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019